
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is projected to generate revenues of $315.0 million, reflecting a 3% growth compared to the previous year, indicating stability and growth potential in its business segments. The firm's adjusted earnings are expected to increase slightly to $0.50 per share, up from $0.49 the prior year, showcasing operational efficiency and profitability. The company maintains a robust presence in key markets, with approximately 55% of its revenue derived from the United States, supporting a diversified global revenue stream that enhances its financial resilience.
Bears say
Bio-Techne's stock outlook is negatively affected by the escalation of US tariffs and proposed cuts of up to 40% in funding for US agencies, including the NIH, which are anticipated to significantly impact revenues and gross margins in the upcoming 4Q25E. The company's exposure to these external factors is expected to result in slower-than-expected revenue growth and profit margins for the current quarter ending June 30. This adjustment to revenue and margin estimates indicates a deterioration in financial performance expectations for the company.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares